COVID-19 & CancerFreeGuest Editorial ASCO data will provide actionable insights from the COVID-19 pandemic—for every patient June 05, 2020Vol.46 No.23By Richard L. Schilsky
FreeGuest Editorial Fostering a culture of gender-based respect and inclusion in oncology June 05, 2020Vol.46 No.23By Narjust Florez, Christina Chapman, Stephanie L. Graff, Tatiana M. Prowell and Miriam A. Knoll
Conversation with The Cancer LetterCOVID-19 & CancerFree Clifford Hudis: What a virtual meeting can accomplish—and what a virtual meeting cannot accomplish June 05, 2020Vol.46 No.23By Paul Goldberg
Conversation with The Cancer LetterFree States with Medicaid expansion have lower overall cancer mortality, study findsNo additional decrease observed in black populations because of worse baseline June 05, 2020Vol.46 No.23By Matthew Bin Han Ong
EditorialFree What We Believe June 05, 2020Vol.46 No.23By Alexandria Carolan, Katie Goldberg, Matthew Bin Han Ong and Paul Goldberg
FreeGuest Editorial I could have been George Floyd—many timesReflecting on the cancer of racism June 05, 2020Vol.46 No.23By Robert A. Winn
Drugs & TargetsFree Opdivo + Yervoy receive FDA approval combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC May 29, 2020Vol.46 No.22
Drugs & TargetsFree Brigatinib receives FDA approval for ALK-positive metastatic NSCLC May 29, 2020Vol.46 No.22
Drugs & TargetsFree CLR 131 receives fast track designation in lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia May 29, 2020Vol.46 No.22
